In short
Clinical trials are studying Acalabrutinib in several blood cancers, especially chronic lymphocytic leukemia, small lymphocytic lymphoma, mantle cell lymphoma, and diffuse large B-cell lymphoma. These studies look at how well it works, how safe it is, and which patients may benefit most. Many trials include older adults, people with relapsed disease, or patients with newly diagnosed high-risk disease.
Key points
- Acalabrutinib is being studied in many clinical trials for blood cancers, especially CLL, SLL, MCL, and DLBCL. The trials include both newly diagnosed patients and people whose disease is relapsed or refractory, meaning it returned or did not respond well to earlier treatment. Most studies are Phase 2 or Phase 3, with a smaller number of Phase 1 and Phase 4 trials. Researchers are measuring outcomes such as progression-free survival, overall response rate, complete remission, minimal residual disease, and safety. Some trials focus on older adults, frail patients, or people with cardiac impairment. Others test Acalabrutinib in combination with treatments such as venetoclax, obinutuzumab, rituximab, or chemotherapy.
Trial overview
The trial data show many studies of Acalabrutinib in blood cancers, with the largest focus on chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The studies include both single-drug and combination treatment plans, and they are being run in different phases, from Phase 1 to Phase 4.
Several trials are already authorised, some are completed, and one trial was withdrawn. The main goal across these studies is to see how well Acalabrutinib works, how safe it is, and whether it helps different patient groups more than other treatments.
Conditions being studied
Most studies focus on CLL and SLL, which are closely related blood cancers that affect lymphocytes, a type of white blood cell. The trials also study Acalabrutinib in mantle cell lymphoma, diffuse large B-cell lymphoma, marginal zone lymphoma, and Waldenström macroglobulinemia.
Some trials are designed for specific higher-risk groups, such as people with high-risk CLL, previously untreated mantle cell lymphoma, relapsed or refractory disease, or older adults with lymphoma or leukemia. One Phase 4 study looks at tumor lysis syndrome risk in people with previously untreated CLL who are receiving venetoclax together with either obinutuzumab or Acalabrutinib.
Trial phases and study goals
Phase 1 trials mainly look at safety, tolerability, dose limits, and the best dose to use in later studies. In one Phase 1 study, Acalabrutinib is being tested in leukemia, including Richter's syndrome and prolymphocytic leukemia, with outcomes that include response, safety, and drug activity in the body.
Phase 2 studies often ask whether the treatment is active against the cancer and whether the response is strong enough to support later testing. Examples include studies in relapsed or refractory mantle cell lymphoma, Waldenström macroglobulinemia, elderly CLL patients, and previously treated marginal zone lymphoma.
Phase 3 trials are larger and usually compare Acalabrutinib-based treatment with another standard treatment or placebo-based plan. These studies include comparisons in untreated CLL, high-risk CLL, untreated mantle cell lymphoma, and untreated diffuse large B-cell lymphoma.
Phase 4 data are also present, showing a study that looks at a safety issue in routine clinical use, specifically the risk of tumor lysis syndrome during venetoclax ramp-up in untreated CLL.
Who the trials are for
The trials include people who have never been treated before, as well as people whose disease has come back after treatment or did not respond well to earlier therapy. Some studies focus on older adults, such as patients over 70 years or over 80 years, and some focus on frail patients, meaning people with less physical reserve and more vulnerability to treatment stress.
One trial specifically includes patients with moderate to severe cardiac impairment, which means heart function problems that are important when choosing treatment. Other studies focus on high-risk CLL, defined in the trial data by features such as 17p-deletion, TP53 mutation, complex karyotype, or unmutated IGHV status.
Main endpoints being measured
The most common endpoint is progression-free survival (PFS), which means the length of time before the cancer gets worse or the patient dies from any cause. Many Phase 3 trials use PFS as the main way to compare Acalabrutinib-based treatment with another treatment.
Another common endpoint is overall response rate (ORR), which measures how many patients have a partial or complete response to treatment. This is used in studies of mantle cell lymphoma, marginal zone lymphoma, and several leukemia trials.
Some trials measure complete remission, minimal residual disease, infection-free survival, duration of response, overall survival, or safety outcomes such as adverse events and serious adverse events. In safety-focused studies, researchers also track treatment stopping, dose reduction, dose delay, and specific safety problems such as cardiovascular events or severe infections.
Study designs and combinations
Many trials test combination therapy, which means Acalabrutinib is given with other anti-cancer drugs such as venetoclax, obinutuzumab, rituximab, bendamustine, or CHOP-based chemotherapy. Some studies compare a combination against another combination, while others compare Acalabrutinib with placebo or with another active drug.
Several trials are randomized, meaning patients are assigned by chance to different treatment groups. Some are open-label, which means both the study team and the patient know which treatment is being given, while others are double-blind, which means the treatment assignment is hidden to reduce bias.
Some studies also use central review or independent review committees to judge results, which helps make the response assessment more consistent and less influenced by one doctor’s opinion.
Key patient groups of interest
The trial data show special attention to patients who may need gentler or more tailored treatment, including older adults, frail patients, and patients with heart disease. This is important because these groups may not tolerate the same treatment approach as younger or fitter patients.
Other studies focus on people with high-risk disease features, such as certain genetic changes or more aggressive lymphoma types, because these patients may need more intensive treatment strategies. A few trials also explore whether stopping treatment after a fixed time, or restarting it later, can still keep the disease under control in selected patients.